The Paradox of Mental Health: Over-Treatment and Under-Recognition
Among all the conditions in the world of health, mental health occupies a unique and paradoxical place.
On
the one hand is over-treatment and over-medicalization of mental health
issues, often fueled by a pharmaceutical industry interested in the
broadening of the boundaries of “illness” and in the creation of more
and wider diagnostic categories and thus markets for “selling sickness.”
On the other hand exists profound under-recognition of the suffering
and breadth of mental health issues affecting millions of people across
geographies, which is a global problem.
As a journal,
PLOS Medicine
has covered both sides of the mental health “coin,” and we continue to
make mental health in general a priority area. We recognize that the
whole of the field of mental health research is relatively
underdeveloped, and that a particular scarcity of clinical trials exists
from outside high-income settings and for non-drug interventions. As a
result, we also support efforts to improve capacity in mental health
research whilst committing to the publication of the state of the art in
research and commentary
[1],
[2].
Over-treatment,
especially when it results from “disease mongering,” is a persistent
and troubling issue. The harms of over-treatment arise from situations
where normal life experiences (such as menopause, shyness, grief, etc.)
are deemed illnesses
[3] or when diseases are “created” from mild problems and symptoms (such as restless legs
syndrome or female sexual
dysfunction)
[4],
[5].
In both situations, people become patients, and their problems are
deemed to need medical treatment when they may not need it or could be
harmed by it, or when nonmedical options are available. Over-diagnosis
and over-treatment have been shown for a range of human conditions
[3], but this phenomenon as it relates to mental health is particularly powerful
[6].
For example, the widespread over-diagnosis of conditions such as
bipolar disorder, autism spectrum disorder, and attention deficit
hyperactivity disorders (ADHD), especially among children, is now being
documented—the US Centers for Disease Control recently estimated that
6.4 million children aged 4 to 17 had received an ADHD diagnosis at some
point in their lives (amounting to 11% of all US children)—a 41%
increase in the last decade that has been met with alarm and concern by
many doctors and parents
[7]. Two thirds of these children are said to be on medication for the condition. Recent Canadian data
[8]
reaffirm the concerns with excessive labeling of normal child behavior
as pathological. Over-diagnosis in mental health risks unnecessary tests
and treatment, the stigma associated with being labeled mentally ill,
and the considerable costs of testing, treatment, and wasting resources
that could be better utilized elsewhere
[3],
[5].
The
recent DSM-5 process is a lightning rod for these concerns: this month's
update of the psychiatric diagnostic manual has been widely criticized
for continuing the tradition of broadening diagnostic categories and
adding new conditions that redefine more people as having mental illness
and in need of pharmaceutical treatment
[9],
[10].
That decisions about DSM-5 categories are made by experts with
financial ties to the industry that benefits most from a widened patient
population
[11],
[12], is particularly worrying.
In perhaps the most dedicated venue for discussions of this topic, the Selling Sickness conferences (
http://www.sellingsickness.com), which
PLOS Medicine
has been instrumental in shaping, have brought together academic
researchers, medical reformers, consumer advocates, and health
journalists with shared interests in examining the problem of disease
mongering and developing strategies and coalitions for change. The
inaugural conference in 2006 coincided with our launch of the
PLOS Medicine Disease Mongering Collection (
http://bit.ly/18i6j6h)
that to this day remains astonishingly relevant. In February 2013 we
participated again, this time in a roundtable on the role of the medical
media where we outlined our responsibility as editors to avoid the spin
in published articles and the journal's press releases that can fuel
hype about new disease categories and treatment
[13];
we also highlighted another important role of journals in fighting
disease mongering: to require that all clinical trials be registered and
data be reported and shared, so that the full picture of the benefits
and harms of tested interventions can be seen (see, for example,
http://www.alltrials.net). The conference's Call to Action petition (
http://sellingsickness.com/final-statement/) is available for readers to view and sign. Later in 2013, two comrade conferences, PharmedOut (
http://www.pharmedout.org/) and Avoiding Overdiagnosis (
http://www.preventingoverdiagnosis.net/),
will continue the conversation about both the extent and the prevention
of over-diagnosis, and will undoubtedly provide new insights into the
problems associated with over-treatment of mental health.
Equally important, however, is the vast
under-recognition
of mental health conditions, especially in the developing world. This
neglect has occurred at multiple levels including at the national level,
where many countries have failed to establish adequate mental health
policy. At the level of global health agendas, mental health was
essentially ignored in the Millennium Development Goal program and
failed to elevate to prominence at the recent United Nations special
assembly on non-communicable disease.
As many others have noted
[14]–
[16],
this neglect makes little sense: more than 13% of the global burden of
disease is attributable to neuropsychiatric disorders, and over 70% of
this burden lies in low- and middle-income countries (LMICs). Almost a
quarter of the world's disability burden is now attributable to mental
and behavioral disorders (including depression, anxiety, Alzheimer
disease, and schizophrenia)
[17].
And yet mental health has failed thus far to receive the political
priority and international funding commensurate with its global toll
[14].
There are signs this tide is shifting, and several prominent groups and
organizations are working to raise the profile of global mental health.
PLOS Medicine has provided a forum for that effort over the last few years, publishing packages of care for mental health disorders in LMICs
[18] and an ongoing series on mental health interventions in practice
[2].
And this week we conclude a five-part series that sets out an agenda
for integrating mental health care into primary care, maternal health,
non-communicable disease, and HIV interventions in the developing world
[19].
All of these analyses were done by researchers free of financial links
to manufacturers with a stake in expanded markets, thus providing the
necessary independent opinion.
In
addition, we've recently published high-quality research on a range of
topics within mental health that contributes to improved clinical
practice, policy, and action. This includes definitive evidence on the
long-term health consequences of sexual abuse
[20] and trafficking
[21], a genome-wide analysis establishing the limited ability of genetic data to predict antidepressant response
[22], and a meta-analysis reporting the relative benefits and harms of adjunctive antipsychotic medications in depression
[23]. These studies add to a growing evidence base, and signal a growing recognition of the importance of mental health.
Still, our understanding of all aspects of mental health is relatively underdeveloped. As others have acknowledged
[3],
[24],
the research base for over-diagnosis and harm from over-treatment
remains limited, and so the new initiatives and calls for action are
welcomed. So too is growing recognition and research on genuine mental
health issues and the best ways to address and prevent mental health
problems, especially in terms of policy and human rights action and in a
global context. To the extent that these two areas (
over-treatment on one hand,
under-recognition
on the other hand) represent the paradox of mental health, where's the
balance point? We don't have all the answers, but as a journal we
reaffirm our commitment to publishing rigorous, insightful research and
commentary on the breadth of issues around global mental health, and we
welcome continued debate on the challenges this paradox represents. The
largest challenge may be to recognize and prioritize mental health
globally—with the requisite political visibility, funding, research, and
attention—without reducing it to an object for disease mongering,
pathologizing, and harmful over-treatment.
Author Contributions
Wrote the first draft of the manuscript: JC. Contributed to the writing of the manuscript: JC PS MW LC AR.
ICMJE criteria for authorship read and met: JC PS MW LC AR. Agree with manuscript results and conclusions: JC PS MW LC AR.
Citation: The
PLOS Medicine Editors (2013) The Paradox of Mental Health: Over-Treatment and Under-Recognition. PLoS Med 10(5):
e1001456.
doi:10.1371/journal.pmed.1001456
Published: May 28, 2013
Copyright:
© 2013 PLoS Medicine Editors. This is an open-access article
distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
Funding: The authors are each paid a salary by the Public Library of Science, and they wrote this editorial during their salaried time.
Competing interests: The authors' individual competing interests are at
http://www.plosmedicine.org/static/editorsInterests.action.
PLOS is funded partly through manuscript publication charges, but the
PLOS Medicine Editors are paid a fixed salary (their salary is not
linked to the number of papers published in the journal).
Abbreviations: ADHD, attention deficit hyperactivity disorders; LMIC, low- and middle-income country
Provenance: Written by editorial staff; not externally peer reviewed.